Dennis M. Brown

Dr. Brown has been involved in cancer drug discovery and development for more than 35 years. Initially at Stanford University in collaboration with SRI International where he was involved in drug-screening activities sponsored by the U.S. National Cancer Institute. Dr. Brown has founded or co-founded multiple companies including Matrix Pharmaceutical, Inc. (acquired by Chiron Corp. in 2002), ChemGenex Pharmaceuticals (acquired by Cephalon/Teva in 2011) and Kintara Therapeutics, Inc. (NASDAQ: KTRA, formerly DelMar Pharmaceuticals, Inc.). During his career, Dr. Brown has been involved in the discovery and development of multiple FDA-approved cancer therapies. He currently serves as a member of the National Brain Tumor Society Research Roundtable, as a consultant to DelMar Pharmaceuticals, as Chairman of Mountain View Pharmaceutical's Board of Directors and is the President of Valent Technologies LLC, which has been involved in the discovery of Edison Oncology's drug candidates. He also previously served as an Assistant Professor of Radiology at Harvard University Medical School and as a Research Associate in Radiology at Stanford University Medical School. He received his B.A. in Biology and Chemistry (1971), M.S. in Cell Biology (1975) and Ph.D. in Radiation and Cancer Biology (1979), all from New York University. Dr. Brown is an inventor of more than 40 issued U.S. patents and applications, many with foreign counterparts.